Androgen Therapy in Women with Diminished Ovarian Reserve
Evidence-based protocols to optimize follicular recruitment, ovarian sensitivity, and egg quality.
At VCRM, we use androgen therapy for women with diminished ovarian reserve, including Testosterone and DHEA, particularly for patients with poor ovarian response, borderline elevated follicle-stimulating hormone (FSH), and low anti-Müllerian hormone levels (AMH < 0.70 ng/mL).
In the human ovary, androgens play an indispensable physiological role during early pre-antral and antral follicle development. Adequate intra-ovarian androgen concentrations promote follicle-stimulating hormone (FSH) receptor expression on granulosa cells and prevent follicular atresia (premature egg cell death), helping recruit more healthy follicles into the IVF stimulation pool.
Low AMH Levels
Particularly beneficial for patients with Anti-Müllerian Hormone (AMH) concentrations below 0.70 ng/mL.
Borderline High FSH
Supports women exhibiting elevated baseline FSH levels indicating decreased ovarian responsiveness.
How Androgen Therapy (Testosterone & DHEA) Works
Priming the follicular microenvironment for improved egg yield and embryo quality.
To maximize ovarian response in poor responders and women with diminished ovarian reserve, Dr. Sharara utilizes two evidence-based androgen priming modalities tailored to each patient's hormonal profile:
Oral DHEA Supplementation
DHEA (Dehydroepiandrosterone) is a weak androgen precursor produced naturally by the adrenal glands and ovaries. Taken as a micronized oral supplement (typically 25 mg three times daily, totaling 75 mg/day) for 8 to 12 weeks prior to ovarian stimulation, DHEA is converted locally within ovarian theca and granulosa cells into active androgens, promoting follicular growth across the 90-day recruitment window.
Testosterone Priming
Testosterone therapy provides direct androgen receptor stimulation. Administered under strict physician guidance (often via transdermal gel or patch protocols in the weeks preceding gonadotropin stimulation), Testosterone directly upregulates FSH receptors on granulosa cells, enhances follicular sensitivity, and significantly improves ovarian responsiveness during the subsequent IVF cycle.
Improved Egg Quality & Euploidy
By increasing the intra-ovarian androgen microenvironment prior to stimulation, androgen priming reduces chromosomal aneuploidy rates, improves embryo development, and enhances fertilization rates in women with diminished ovarian reserve.
A Second Chance to Conceive with Your Own Biological Eggs
Proven alternatives before moving to donor eggs or adoption.
For patients diagnosed with diminished ovarian reserve, elevated FSH, or very low AMH, androgen therapy can make a meaningful clinical difference in egg yield and blastocyst quality.
With personalized androgen priming protocols, many women previously advised that donor egg IVF was their only option have successfully achieved pregnancy using their own biological eggs—allowing families to pursue all autologous conception options with confidence.
Medical Supervision & Monitoring Essential
Androgen therapy involves active hormones and must never be taken without specialized reproductive endocrinologist supervision and serial blood monitoring. Women with PCOS, high baseline androgen levels, or hormone-sensitive conditions should avoid androgen supplementation. At VCRM, Dr. Sharara performs comprehensive baseline hormonal panels including DHEA-S, total testosterone, and free testosterone before initiating any priming regimen.
Individualized Clinical Protocols at VCRM
Evidence-based androgen priming supervised directly by Dr. Fady Sharara.
At VCRM, Dr. Sharara designs customized androgen priming protocols incorporating DHEA and Testosterone for women with diminished ovarian reserve prior to their IVF stimulation cycles. To learn more about our androgen therapy protocols and determine the optimal treatment plan for your fertility journey, please contact our Virginia fertility center to schedule a consultation with Dr. Sharara.
Frequently Asked Questions About Androgen Therapy & Diminished Reserve
Common questions regarding dosage, timing, testosterone vs. DHEA, and monitoring.
How does Dr. Sharara determine between DHEA and Testosterone priming?
Dr. Sharara evaluates your baseline hormonal profile—including AMH, Day 3 FSH, antral follicle count, baseline total testosterone, and DHEA-S levels—along with your past stimulation response history. Depending on your timeline and hormone levels, he may recommend oral DHEA, transdermal Testosterone, or a coordinated protocol to optimize follicle recruitment.
What is the standard recommended duration for androgen priming?
Oral DHEA is typically taken for 8 to 12 weeks prior to starting an IVF cycle to support the full 90-day follicle maturation window. Testosterone priming is often administered for 2 to 4 weeks immediately preceding ovarian stimulation. Blood levels are periodically monitored to ensure optimal therapeutic ranges.
Are there side effects associated with androgen therapy?
Because DHEA and testosterone are androgens, mild dose-dependent side effects may include oily skin, occasional acne, or minor hair shedding. These are monitored closely by Dr. Sharara and resolve after priming is completed.
Can androgen therapy be combined with CoQ10 and other supplements?
Yes. Androgen priming is frequently paired with high-absorption CoQ10 (Ubiquinol), Vitamin D3, and targeted antioxidants as part of a comprehensive ovarian support protocol to boost mitochondrial energy in maturing oocytes.
When is androgen therapy discontinued?
Androgen medications are stopped at the start of gonadotropin stimulation or on the day of trigger/egg retrieval as instructed by Dr. Sharara, ensuring no exogenous androgens remain during embryo transfer or early pregnancy.